Related Experiment Video
Updated: Apr 10, 2026
Author Spotlight: Scalable Drug Screening Protocol for Efficient Discovery of M. abscessus Treatments
Published on: October 25, 2024
Drug screening to identify compounds to eliminate Burkholderia pseudomallei through Hcp protein
Chuizhe Chen1,2, Xuemiao Li1, Xin Li3
1NHC Key Laboratory of Tropical Disease Control, School of Life Sciences and Medical Technology, Hainan Medical University, Haikou, Hainan 571199, China.
Abstract:
Burkholderia pseudomallei (B. pseudomallei) exhibits inherent resistance to multiple antibiotics and Strong pathogenicity, highlighting the urgent need for effective antibiotics. The type VI secretion system (T6SS) is a key virulence factor in B. pseudomallei, and its core structural protein hemolysin coregulated protein (Hcp) represents a conserved, essential target for potential intervention. In this study, Hcp was utilized as a molecular target to screen antibacterial agents from the FDA Orange Book database. Subsequent functional assays and mechanistic analyses identified netilmicin sulfate, which specifically binds to Hcp and exhibits a potent bacteriostatic effect. In vitro and in vivo studies demonstrated that it effectively eliminates B. pseudomallei and enhances host survival post-infection. Combination with ceftazidime exhibits synergism, strengthening host cell protection and reducing the required dosage. Mechanistically, it disrupts Hcp's tubular structure, compromising T6SS functional architecture and attenuating B. pseudomallei viability. Beyond identifying a promising antibiotic candidate, this approach underscores a potential strategy for future antimicrobial drug discovery targeting T6SS components.
Insights
Netilmicin sulfate effectively targets the Burkholderia pseudomallei type VI secretion system (T6SS) protein Hcp, offering a new strategy against this dangerous pathogen. This discovery provides a promising antibiotic candidate and a novel approach for antimicrobial drug discovery.
Area of Science:
- Microbiology
- Drug Discovery
- Infectious Diseases
Background:
- * Burkholderia pseudomallei (B. pseudomallei) is a highly pathogenic bacterium known for its inherent antibiotic resistance.
- * The type VI secretion system (T6SS) is a critical virulence factor in B. pseudomallei, making its components attractive targets for therapeutic intervention.
Purpose of the Study:
- * To identify novel antibacterial agents targeting the T6SS of B. pseudomallei.
- * To investigate the mechanism of action and efficacy of identified compounds against B. pseudomallei.
Main Methods:
- * Screening of the FDA Orange Book database for agents targeting the T6SS core protein Hcp.
- * In vitro and in vivo functional assays to evaluate antibacterial activity and host survival.
- * Mechanistic studies to elucidate the disruption of T6SS architecture by the identified agent.
Main Results:
- * Netilmicin sulfate was identified as a specific binder of Hcp, exhibiting potent bacteriostatic effects against B. pseudomallei.
- * In vitro and in vivo studies confirmed netilmicin sulfate's efficacy in eliminating B. pseudomallei and enhancing host survival.
- * Combination therapy with ceftazidime demonstrated synergistic effects, improving host protection and reducing drug dosage.
Conclusions:
- * Netilmicin sulfate represents a promising antibiotic candidate for treating B. pseudomallei infections by targeting T6SS.
- * Disruption of Hcp's structure by netilmicin sulfate compromises T6SS function, leading to bacterial attenuation.
- * This study validates T6SS components as viable targets for developing new antimicrobial strategies.
More Related Videos
11:31Establishment of a High-throughput Setup for Screening Small Molecules That Modulate c-di-GMP Signaling in Pseudomonas aeruginosa
Published on: June 30, 2016
09:57System for Efficacy and Cytotoxicity Screening of Inhibitors Targeting Intracellular Mycobacterium tuberculosis
Published on: April 5, 2017